Vvardis closes on $35M in financing

Swiss dental company vVardis secured $35 million in funding from healthcare investment firm OrbiMed for global expansion.

VVardis develops Curodont, a gel that is formulated to address early tooth decay with a drill-free, noninvasive treatment.

Page 1 of 155
Next Page